A clinical trial update for anamorelin was recorded on June 18, 2026. The study, registered as NCT03035409, is titled "Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors."
The trial is listed as Phase 2 and its current status is active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time.
The trial evaluates anamorelin in combination with physical activity and nutritional counseling in patients with incurable metastatic or recurrent solid tumors, focusing on cancer-related fatigue. No results have been reported as part of this update.
Anamorelin remains classified as an unapproved compound under research investigation. It has not received regulatory approval for the indication studied in this trial or for any other use.
This update reflects only the trial's registration status and design as listed on ClinicalTrials.gov. No efficacy or safety conclusions can be drawn from a status change alone. Readers can review the compound overview for additional background and context on anamorelin's research status.